The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Cigna has made numerous forays into the GLP-1 space. Last year, the company launched EncircleRx to provide savings guarantees or caps on GLP-1 weight-loss drug spending to customers, which ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 drugs ... respectively—to cap patients' monthly costs at $200.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients’ copays for pricey GLP-1 weight loss medications, the health services business announced ...

Cigna’s (NYSE:CI) health services arm ... Zepbound. The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200 under the new offering. Patients can save as much ...

The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)’s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly’s ...